Piper Sandler Issues Pessimistic Forecast for Keros Therapeutics (NASDAQ:KROS) Stock Price

Keros Therapeutics (NASDAQ:KROS) had its price target cut by investment analysts at Piper Sandler from $40.00 to $15.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s target price indicates a potential upside of 38.12% from the stock’s current price.

Several other equities research analysts have also recently weighed in on KROS. Scotiabank decreased their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday. Wedbush lowered shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $47.00 to $15.00 in a report on Friday. BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. HC Wainwright reduced their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, Oppenheimer lowered their price objective on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Keros Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $52.56.

Keros Therapeutics Trading Up 3.2 %

KROS opened at $10.86 on Friday. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The company has a market cap of $439.94 million, a PE ratio of -2.08 and a beta of 1.43. The company has a 50 day moving average of $36.37 and a 200 day moving average of $47.13.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million during the quarter. During the same period in the prior year, the firm earned ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% on a year-over-year basis. Research analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV lifted its position in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics in the 2nd quarter valued at $128,000. Finally, LMR Partners LLP bought a new position in shares of Keros Therapeutics during the 3rd quarter valued at $213,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.